The results of another preclinical study (137) conducted in vivo with SSTR2 positive cells and in mice with tumors, showed that the tumor uptake was five times more with SSTR2 radiolabeled antagonists, 177Lu-DOTA-JR11, compared to the SSTR2 radiolabeled agonist, 177Lu-DOTA-octreotate, which led to a longer delay in growth. The gene discussed is SSTR2; the disease is neoplasm.